Axogen Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Axogen Inc trades at $48.85 (market cap $2.59B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 32.1× Axogen Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | REGN | |
|---|---|---|
Market Cap | $2.59B | $83.19B |
Sector | Technology | Health |
52-Week High | $48.48 | $812.27 |
52-Week Low | $14.16 | $555.51 |
Enterprise Value | $2.50B | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →